Delcath Systems Inc (DCTH.PK)
14 Sep 2017
Latest Key Developments (Source: Significant Developments)
Delcath Systems Inc
Delcath Systems Inc: Delcath announces second quarter financial results . Qtrly loss per share $4.41 . Q2 revenue $500,000 .Delcath believes it has sufficient capital to fund its operating activities through end of 2017. Full Article
Delcath Systems Inc:Announces the initiation of a Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) for the treatment of patients with hepatic dominant ocular melanoma (OM).Says moffitt cancer center begins patient enrollment in focus trial; study results to support u.s. new drug application. Full Article
* Delcath Systems - CEO issued letter to stockholders providing business update, "rationale for company's recent actions to preserve access to capital"